Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt dise… Read more
Abeona Therapeutics Inc (ABEO) - Net Assets
Latest net assets as of September 2025: $171.23 Million USD
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has net assets worth $171.23 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($231.09 Million) and total liabilities ($59.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $171.23 Million |
| % of Total Assets | 74.1% |
| Annual Growth Rate | 11.91% |
| 5-Year Change | -57.06% |
| 10-Year Change | -34.98% |
| Growth Volatility | 589.24 |
Abeona Therapeutics Inc - Net Assets Trend (1995–2024)
This chart illustrates how Abeona Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abeona Therapeutics Inc (1995–2024)
The table below shows the annual net assets of Abeona Therapeutics Inc from 1995 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $44.03 Million | +196.99% |
| 2023-12-31 | $14.83 Million | -44.60% |
| 2022-12-31 | $26.76 Million | -36.84% |
| 2021-12-31 | $42.37 Million | -58.69% |
| 2020-12-31 | $102.55 Million | -42.53% |
| 2019-12-31 | $178.43 Million | +33.11% |
| 2018-12-31 | $134.04 Million | -21.20% |
| 2017-12-31 | $170.10 Million | +71.65% |
| 2016-12-31 | $99.10 Million | +46.33% |
| 2015-12-31 | $67.72 Million | +1306.17% |
| 2014-12-31 | $4.82 Million | +132.59% |
| 2013-12-31 | $-14.78 Million | +13.45% |
| 2012-12-31 | $-17.08 Million | +3.01% |
| 2011-12-31 | $-17.61 Million | +15.34% |
| 2010-12-31 | $-20.80 Million | +22.95% |
| 2009-12-31 | $-26.99 Million | -141.27% |
| 2008-12-31 | $-11.19 Million | -1742.58% |
| 2007-12-31 | $681.00K | +106.89% |
| 2006-12-31 | $-9.89 Million | -133.35% |
| 2005-12-31 | $-4.24 Million | +36.39% |
| 2004-12-31 | $-6.66 Million | -14.35% |
| 2003-12-31 | $-5.83 Million | -1291.21% |
| 2002-12-31 | $489.00K | -94.61% |
| 2001-12-31 | $9.08 Million | -39.50% |
| 2000-12-31 | $15.00 Million | +316.78% |
| 1999-12-31 | $3.60 Million | +100.00% |
| 1998-12-31 | $1.80 Million | +200.50% |
| 1997-12-31 | $599.00K | -85.25% |
| 1996-12-31 | $4.06 Million | +140.81% |
| 1995-12-31 | $1.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abeona Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77423200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $457.00K | 1.04% |
| Other Comprehensive Income | $8.00K | 0.02% |
| Other Components | $856.82 Million | 1945.96% |
| Total Equity | $44.03 Million | 100.00% |
Abeona Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Abeona Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
$202.85 Million |
|
Nanchang Mineral Systems Co. Ltd. A
SHE:001360
|
$202.86 Million |
|
Ahluwalia Contracts (India) Limited
NSE:AHLUCONT
|
$202.86 Million |
|
Elematec Corporation
PINK:EEAEF
|
$202.87 Million |
|
Vastned Retail NV
AS:VASTN
|
$202.76 Million |
|
Shenzhen Water Planning & Design Institute Co. Ltd.
SHE:301038
|
$202.63 Million |
|
NUIX Ltd
AU:NXL
|
$202.62 Million |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
$202.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abeona Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,826,000 to 44,031,000, a change of 29,205,000 (197.0%).
- Net loss of 63,734,000 reduced equity.
- New share issuances of 85,628,000 increased equity.
- Other comprehensive income increased equity by 74,000.
- Other factors increased equity by 7,237,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.73 Million | -144.75% |
| Share Issuances | $85.63 Million | +194.47% |
| Other Comprehensive Income | $74.00K | +0.17% |
| Other Changes | $7.24 Million | +16.44% |
| Total Change | $- | 196.99% |
Book Value vs Market Value Analysis
This analysis compares Abeona Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 4.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $4215.00 | $4.76 | x |
| 1996-12-31 | $10150.00 | $4.76 | x |
| 1997-12-31 | $1497.50 | $4.76 | x |
| 1998-12-31 | $3284.67 | $4.76 | x |
| 1999-12-31 | $3696.10 | $4.76 | x |
| 2000-12-31 | $8496.04 | $4.76 | x |
| 2001-12-31 | $4413.22 | $4.76 | x |
| 2002-12-31 | $233.30 | $4.76 | x |
| 2003-12-31 | $-2745.05 | $4.76 | x |
| 2004-12-31 | $-2746.80 | $4.76 | x |
| 2005-12-31 | $-1636.54 | $4.76 | x |
| 2006-12-31 | $-3499.82 | $4.76 | x |
| 2007-12-31 | $239.70 | $4.76 | x |
| 2008-12-31 | $-1673.80 | $4.76 | x |
| 2009-12-31 | $-2854.77 | $4.76 | x |
| 2010-12-31 | $-1662.80 | $4.76 | x |
| 2011-12-31 | $-1101.34 | $4.76 | x |
| 2012-12-31 | $-882.80 | $4.76 | x |
| 2013-12-31 | $-725.24 | $4.76 | x |
| 2014-12-31 | $247.88 | $4.76 | x |
| 2015-12-31 | $61.34 | $4.76 | x |
| 2016-12-31 | $72.49 | $4.76 | x |
| 2017-12-31 | $102.16 | $4.76 | x |
| 2018-12-31 | $70.51 | $4.76 | x |
| 2019-12-31 | $88.59 | $4.76 | x |
| 2020-12-31 | $27.66 | $4.76 | x |
| 2021-12-31 | $10.76 | $4.76 | x |
| 2022-12-31 | $3.40 | $4.76 | x |
| 2023-12-31 | $0.69 | $4.76 | x |
| 2024-12-31 | $1.07 | $4.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abeona Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -144.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.47x
- Recent ROE (-144.75%) is above the historical average (-271.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 20.23% | 11.58% | 1.38x | 1.26x | $172.40K |
| 1996 | -282.32% | -6863.47% | 0.03x | 1.21x | $-11.87 Million |
| 1997 | -741.40% | -1020.92% | 0.30x | 2.42x | $-4.50 Million |
| 1998 | -188.89% | -3400.00% | 0.04x | 1.33x | $-3.58 Million |
| 1999 | -91.89% | -22053.33% | 0.00x | 1.28x | $-3.67 Million |
| 2000 | -36.18% | -5072.90% | 0.00x | 2.03x | $-6.93 Million |
| 2001 | -66.39% | -2480.25% | 0.01x | 2.81x | $-6.93 Million |
| 2002 | -1919.02% | -818.13% | 0.06x | 39.85x | $-9.43 Million |
| 2003 | 0.00% | -535.52% | 0.11x | 0.00x | $-6.35 Million |
| 2004 | 0.00% | -1864.85% | 0.05x | 0.00x | $-9.57 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.28 Million |
| 2006 | 0.00% | -2.34% | 85.59x | 0.00x | $-11.89 Million |
| 2007 | -3192.95% | -38147.37% | 0.01x | 13.43x | $-21.81 Million |
| 2008 | 0.00% | -10801.03% | 0.07x | 0.00x | $-30.31 Million |
| 2009 | 0.00% | -4926.14% | 0.22x | 0.00x | $-14.64 Million |
| 2010 | 0.00% | -1566.94% | 0.05x | 0.00x | $-5.46 Million |
| 2011 | 0.00% | -137.01% | 0.49x | 0.00x | $-771.40K |
| 2012 | 0.00% | -239.15% | 2.55x | 0.00x | $-8.82 Million |
| 2013 | 0.00% | 217.87% | 3.33x | 0.00x | $5.93 Million |
| 2014 | -556.02% | -2894.92% | 0.06x | 3.44x | $-27.26 Million |
| 2015 | -21.45% | -1396.73% | 0.01x | 1.18x | $-21.30 Million |
| 2016 | -22.07% | -2460.40% | 0.01x | 1.12x | $-31.78 Million |
| 2017 | -16.06% | -3263.92% | 0.00x | 1.05x | $-44.33 Million |
| 2018 | -42.28% | -1890.29% | 0.02x | 1.30x | $-70.08 Million |
| 2019 | -42.75% | 0.00% | 0.00x | 1.25x | $-94.12 Million |
| 2020 | -82.14% | -842.34% | 0.07x | 1.47x | $-94.49 Million |
| 2021 | -200.47% | -2831.20% | 0.04x | 1.88x | $-89.17 Million |
| 2022 | -148.34% | -2807.36% | 0.02x | 2.40x | $-42.37 Million |
| 2023 | -365.49% | -1548.23% | 0.05x | 4.32x | $-55.67 Million |
| 2024 | -144.75% | 0.00% | 0.00x | 2.47x | $-68.14 Million |
Industry Comparison
This section compares Abeona Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $65,593,376
- Average return on equity (ROE) among peers: -165.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abeona Therapeutics Inc (ABEO) | $171.23 Million | 20.23% | 0.35x | $202.79 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |